Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KRAS | P01116 | 1/20 | 0.38 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | PKM | P14618 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7578585 | 0.85 | KRAS (0.51) | KDM4EALDH1A1KRASNPC1RAB9A | |
| SCHEMBL10206036 | 0.81 | DDAH1 (0.59) | KDM4CKRASDDAH1POLBPDE3B | |
| SCHEMBL5806722 | 0.81 | TDP1 (0.49) | KDM4CKRASDDAH1POLBPDE3B | |
| SCHEMBL31875233 | 0.81 | CACNA1H (0.44) | KDM4CKRASDDAH1POLBPDE3B | |
| SCHEMBL4072911 | 0.81 | CACNA1H (0.44) | KDM4CKRASDDAH1POLBPDE3B | |
| Hydrochloric Acid SCHEMBL27147079 | 0.80 | CACNA1H (0.42) | KDM4CKRASDDAH1POLBPDE3B | |
| SCHEMBL9851482 | 0.79 | KDM4C (0.63) | KDM4CKDM4EDDAH1POLBNPC1 | |
| SCHEMBL9598111 | 0.79 | KDM4C (0.44) | KDM4CKDM4EKRASPOLBNPC1 | |
| SCHEMBL9569918 | 0.79 | KDM4C (0.48) | KDM4CKDM4EKRASPOLBPDE3B | |
| SCHEMBL11955037 | 0.77 | KDM4C (0.40) | KDM4CKRASDDAH1POLBPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020151550-A1 | Aryl and heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of bradykinin B2 receptors | NEUROGEN CORPORATION (US) | 2002-10-17 | — | — | US | disclosed |
| US-20020082425-A1 | For therapy of obesity and diabetes | NEUROGEN CORPORATION | 2002-06-27 | — | — | US | disclosed |
| US-6358949-B1 | CARDIOVASCULAR AND SEXUAL DISORDERS; DIABETES, KIDNEY DISEASE, LIVER CIRRHOSIS; ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIASTHMATICS | NEUROGEN CORPORATION | 2002-03-19 | — | — | US | disclosed |
| US-6271241-B1 | BENZYLIMIDAZOLE DERIVATIVES AS MODULATORS OF BLOOD GLUCOSE LEVELS, ALSO USEFUL AS PROBES FOR LOCALIZATION OF CELLULAR RECEPTORS INVOLVED WITH SUCH MODULATION; FOOD METABOLISM AND FEEDING; TREATING DIABETES, OBESITY | NEUROGEN CORPORATION | 2001-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082425-A1 | For therapy of obesity and diabetes | GPR119, GLP1R, NPY1R | KDM4C 3247/4885KDM4E 3600/4885ALDH1A1 363/4885 |
| US-20020151550-A1 | Aryl and heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of bradykinin B2 receptors | BDKRB2, BDKRB1, HRH2 | KDM4C 3793/4885KDM4E 3819/4885ALDH1A1 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.